Page 5 - Pharma Analyst News Today

The Covid-19 vaccination drive for children below the age of 18 might revive India's stuttering programme of mass inoculation of adolescents against other diseases

25 Jan 2022 Novavax continues to strengthen Asia presence with South Korea approval, says GlobalData Posted in Pharma American biotech... | January 25, 2022

Promising Atopic Dermatitis Treatment A major force in the atopic dermatitis (AD) space is Topical Janus kinase (JAK) inhibitors. Recently, an increasing number of JAK agents are filling the early and late-stage pipeline. Ramla Salad, Pharma Analyst at Global Data, comments "JAK inhibitors can combat AD at the immune system level due to their broad inhibitory effect. They are being developed in both oral and topical formulations, which target both mild-to-moderate and moderate-to-severe respe...

Search jobs Roche leads industry sponsored oncology trials in Australia, says GlobalData Australia has the highest age-standardized incidence rate for all cancers in the world and one of the countries with substantial cancer screening programs. Against this backdrop, several pharma companies are conducting clinical trials related to cancer drugs in the country. Among these, Roche continues to be a key player with the highest number of clinical trials in oncology indica...

Chinese COVID-19 vaccines crucial for developing nations: GlobalData Chinese COVID-19 vaccines crucial for developing nations: GlobalData 23 April 2021 | News China has so far provided COVID-19 vaccine aid to more than 50 developing nations and Sinovac Biotech alone has already supplied over 150 million doses to other countries Source credit: Shutterstock Beijing-based pharmaceutical company Sinovac Biotech’s CoronaVac vaccine was recently found to be 49.6 per cent effective in real-...

Current therapies for new SARS-CoV-2 variants require adjustments: GlobalData Current therapies for new SARS-CoV-2 variants require adjustments: GlobalData 23 April 2021 | News Source credit: Shutterstock The emergence of new SARS-CoV-2 variants have been detected in over 40 countries and are disrupting drug development worldwide. The prevalence of these more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy, says Glo...

Sputnik V to face stiff competition in India: GlobalData Sputnik V to face stiff competition in India: GlobalData 20 April 2021 | News Source credit: Shutterstock With the Sputnik V vaccine’s recent approval, India now has three vaccines authorised for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/ AstraZeneca’s Covishield and Bharat Biotech’s COVAXIN, Sputnik V will face stiff competition in India, says GlobalData. Dr Reddys Laboratories (DRL) wi...

CAR-T therapy leads Singapore medical tourism within APAC 12 April 2021 | Analysis With the approval of Novartis’ Kymriah, Singapore is becoming a popular medical tourism destination within APAC: says GlobalData Photo Credit: GlobalData The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are gaining traction. With the approval of Novartis’ Kym...

An interim analysis reveals the Covaxin® (BBV152) vaccine was relatively safe and 81 percent effective in preventing symptomatic COVID-19.

This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cook...